ORIC-944

ORIC Pharmaceuticals Announces Promising Early Data for ORIC-944 and Collaboration for ORIC-114

4 months ago

• ORIC Pharmaceuticals reported encouraging early data from a Phase 1b trial of ORIC-944 combined with apalutamide in metastatic castration-resistant prostate cancer (mCRPC). • The company entered a clinical trial collaboration with Johnson & Johnson to evaluate ORIC-114 with amivantamab for first-line treatment of NSCLC with EGFR exon 20 insertion mutations. • ORIC anticipates seven data readouts across ORIC-114 and ORIC-944 programs in the next 18 months, potentially leading to registrational trials in 2025 and 2026.

Unicycive and ORIC Pharmaceuticals Receive Buy Ratings Based on Promising Clinical Data

4 months ago

• Unicycive Therapeutics' OLC shows promise in treating hyperphosphatemia by reducing pill burden and adverse events, potentially gaining FDA approval by June 2025. • ORIC Pharmaceuticals' ORIC-944, combined with apalutamide, demonstrates significant PSA level decreases in metastatic castration-resistant prostate cancer patients. • Durability of ORIC-944 responses, with some patients maintaining PSA90 responses for 38 weeks, supports confidence in Oric Pharmaceuticals' strategic advancements. • H.C. Wainwright analyst Ed Arce maintains a Buy rating on Unicycive with a $4.00 price target, while Robert Burns reiterates a Buy rating on Oric with a $21.00 target.

Oncolytics Biotech and Bio-Path Holdings Announce Promising Cancer Therapy Advancements

6 months ago

• Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers. • A GOBLET study cohort showed a 33% objective response rate in relapsed anal cancer patients treated with pelareorep and atezolizumab, including a complete response lasting over 15 months. • Bio-Path Holdings reported a meaningful patient response in a Phase 1/1b trial of BP1002 for refractory/relapsed AML, with stable disease and reduced blast count after one treatment cycle. • Bio-Path Holdings' BP1001-A demonstrated continued tumor reduction and stable disease in a solid tumor patient, alongside durable remissions in AML patients treated with prexigebersen.

ORIC-114 Demonstrates Potential in Preclinical Cancer Study

7 months ago

ORIC Pharmaceuticals' drug candidate ORIC-114 has shown promising preclinical results for treating non-small cell lung cancer with specific mutations, demonstrating superior potency and selectivity. The drug is currently under evaluation in a global clinical trial, with updated data anticipated in the first half of 2025.

ORIC Pharmaceuticals Maintains Buy Rating Amidst Competitive Landscape

8 months ago

H.C. Wainwright reaffirms its Buy rating and $21 price target for ORIC Pharmaceuticals, following a review of competitor Ipsen's trial results at the ESMO 2024 conference. Despite Ipsen's positive outcomes, ORIC's potential in prostate cancer treatments and its financial stability keep investor confidence high.

Stifel Initiates Coverage on ORIC Pharmaceuticals with Buy Rating and $20 Target

9 months ago

Stifel has initiated coverage on ORIC Pharmaceuticals with a Buy rating and a $20 price target, highlighting the company's potential in prostate cancer treatments, especially its ORIC-944 product expected to enter phase 3 trials in 2025. ORIC Pharmaceuticals is noted for its innovative approach to treating metastatic castration-resistant prostate cancer, with ORIC-944 utilizing PRC2 inhibition in combination with androgen receptor pathway inhibitors.

ORIC Pharmaceuticals Unveils Promising Cancer Drug Data at AACR Meeting

a year ago

ORIC Pharmaceuticals presented new data on two cancer drug candidates, ORIC-944 and ORIC-613, at the AACR Annual Meeting, showing potential in overcoming therapeutic resistance in cancer. ORIC-944 targets prostate cancer with a promising clinical half-life, while ORIC-613 shows synthetic lethality in TRIM37-high tumor models.